Sugi Predict

Sugi Predict / Compounds / SCHEMBL4295826

SCHEMBL4295826

SCHEMBL4295826

Cc1ccc(C2C(c3c[nH]c4ccccc34)=C(O)C(=O)N2CCCn2ccnc2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.47
▸ PPARG P37231 1/20 0.46
▸ NCOR2 Q9Y618 1/20 0.46
▸ RXFP1 Q9HBX9 4/20 0.46
▸ ALOX15 P16050 2/20 0.46
▸ MAPK10 P53779 2/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2C9 P11712 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ GSK3B P49841 1/20 0.46
▸ QPCT Q16769 1/20 0.46
▸ FPR1 P21462 2/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293708 0.90 QPCT (0.44) KDM4EPPARGNCOR2RXFP1CYP1A2
SCHEMBL4299720 0.87 RXFP1 (0.53) KDM4ERXFP1ALOX15CYP1A2CYP3A4
SCHEMBL3810523 0.86 KDM4E (0.62) KDM4ERXFP1ALOX15MAPK10CYP1A2
SCHEMBL4300546 0.86 QPCT (0.49) KDM4ERXFP1CYP1A2CYP3A4CYP2C9
SCHEMBL3811117 0.86 RXFP1 (0.55) KDM4ERXFP1CYP1A2CYP3A4CYP2C9
SCHEMBL4296931 0.86 QPCT (0.51) KDM4ERXFP1MAPK10CYP1A2CYP3A4
SCHEMBL4297936 0.85 ANXA2 (0.52) KDM4ERXFP1CYP1A2CYP3A4CYP2C9
SCHEMBL4301880 0.84 QPCT (0.48) KDM4ERXFP1CYP1A2CYP3A4CYP2C9
SCHEMBL4293474 0.84 KDM4E (0.52) KDM4ERXFP1CYP1A2CYP3A4CYP2C9
SCHEMBL3815576 0.84 KDM4E (0.51) KDM4EPPARGNCOR2RXFP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 — — US claimed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 — — US claimed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 — — US disclosed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 — — US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 — — US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 — — US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 — — US disclosed
WO-2008055945-A1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2008-05-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL KDM4E 2532/4885PPARG 799/4885NCOR2 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.